Stock SCD ZENTIVA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Zentiva S.A. Stock

Equities

SCD

ROSCDBACNOR8

Pharmaceuticals

End-of-day quote Bucharest S.E.
Other stock markets
 18:00:00 2024-04-25 EDT 		5-day change 1st Jan Change
3.38 RON +1.20% Intraday chart for Zentiva S.A. +6.29% +15.75%
04-01 Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution CI
02-29 Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 760M 164M 224M Sales 2023 954M 206M 282M Capitalization 2.04B 440M 601M
Net income 2022 99M 21.39M 29.23M Net income 2023 193M 41.69M 56.99M EV / Sales 2022 1.79 x
Net Debt 2022 7.62M 1.65M 2.25M Net cash position 2023 6.15M 1.33M 1.82M EV / Sales 2023 2.13 x
P/E ratio 2022
13.6 x
P/E ratio 2023
10.6 x
Employees 952
Yield 2022 *
-
Yield 2023
-
Free-Float 4.05%
More Fundamentals * Assessed data

Chart Zentiva S.A.

Dynamic Chart

Latest news about Zentiva S.A.

Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution CI
Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zentiva S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zentiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zentiva S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology CI
Zentiva S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zentiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zentiva S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Exclusive-Polish drug maker Polpharma working on bid for Advent's Zentiva - sources RE
Zentiva S.A. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Zentiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Mabion S A : Big pharma and private equity seek healthy returns in Europe's east RE
More news

Press releases Zentiva S.A.

Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K. AQ
Zentiva S A : Convening notice Zentiva S.A. – OGMS and EGMS_29.04.2024 PU
Zentiva S A : Memo_Substantiation note_OGMS_29.04.2024 PU
Zentiva S A : Draft Resolution_OGMS_29.04.2024 PU
Zentiva S A : SCD_Zentiva_Fin report 30.06.2023-EN PU
More press releases

News in other languages on Zentiva S.A.

Sanofi : compte vendre un site de fabrication pharmaceutique en Inde à Zentiva
Bristol Myers Squibb : charge deux banques de la vente d'Upsa
Bristol-Myers Squibb charge deux banques de la vente d'Upsa-sces
More news

Quotes and Performance

1 day+1.20%
1 week+6.29%
Current month+13.42%
1 month+11.92%
3 months+16.55%
6 months+48.25%
Current year+15.75%
More quotes

Highs and lows

1 week
3.18
Extreme 3.18
3.38
1 month
2.90
Extreme 2.9
3.38
Current year
2.78
Extreme 2.78
3.38
1 year
1.79
Extreme 1.79
3.38
3 years
1.70
Extreme 1.7
3.38
5 years
1.70
Extreme 1.7
5.34
10 years
1.10
Extreme 1.101
5.34
More quotes

Managers and Directors - Zentiva S.A.

Managers TitleAgeSince
Simona Cocos CEO
 Chief Executive Officer 57 09-09-30
Daniel Nitulescu DFI
 Director of Finance/CFO - -
Margareta Tanase BRD
 Director/Board Member 64 99-12-31
Members of the board TitleAgeSince
Simona Cocos CEO
 Chief Executive Officer 57 09-09-30
Margareta Tanase BRD
 Director/Board Member 64 99-12-31
Francois Noel Merchand BRD
 Director/Board Member 53 17-02-19
More insiders

Quotes

Date Price Change Volume
24-04-26 3.38 +1.20% 1,555
24-04-25 3.34 0.00% 9
24-04-24 3.34 +1.83% 6,221
24-04-23 3.28 0.00% 1,730
24-04-22 3.28 +3.14% 14,054

End-of-day quote Bucharest S.E., April 25, 2024

More quotes

Company Profile

Zentiva SA is a Romania-based company engaged in the pharmaceutical industry. The Company is primarily engaged in the production and commercialization of pharmaceutical preparations. The Company’s portfolio includes approximately 280 products and drugs for cardiovascular, nervous and digestive systems; pain treatment, and urological and anti-inflammatory diseases, among others. Additionally, the Company is active in the production of dietary supplements and vitamins. It has production sites in Czech Republic, Slovakia, Romania and Turkey. As of December 31, 2011, Venoma Holdings Limited held a 50.98% stake in Zentiva SA. The Company had one wholly owned subsidiary, Pallady Business Park SRL, as of December 31, 2011.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
ZENTIVA S.A. Stock Zentiva S.A.
+15.75% 505M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.62% 43.34B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.44% 21.96B
SANDOZ GROUP AG Stock Sandoz Group AG
+10.86% 14.09B
CIPLA LIMITED Stock Cipla Limited
+13.07% 13.64B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+37.46% 11.43B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.59% 6.86B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+8.46% 5.22B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SCD Stock